Epic Update : Aurobindo Pharma

Aurobindo Pharma has received the tentative approval to manufacture and market Efavirenz+Lamivudine+Tenofovir Disoproxil Fumarate Tablets, 600mg/ 300mg/ 300mg from the US Food & Drug Administration (USFDA). The New Drug Application (NDA) 22-343 provides for the use of these tablets alone or in combination with other antiretrovirals for the treatment of HIV-1 infection in adults and adolescents aged more than 16 years of age and weighing at-least 40 kg. 

Get Free MCX Tips, Stock Tips, Forex Tips & NCDEX Tips,Commodity Tips, Share Tips, commodity tips free trial, nifty free tips, commodity trading tips, shares tips, Share Market Tips, Stock Market Tips, free stock tips on mobile, Stock trading tips, Intraday Tips. or login http://www.epicresearch.co/